Telefon:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@antikoerper-online.de

VHL Antikörper (AA 6-175)

VHL Reaktivität: Ratte WB, IHC, IP, ICC Wirt: Kaninchen Polyclonal unconjugated
Produktnummer ABIN1872243
  • Target Alle VHL Antikörper anzeigen
    VHL (Von Hippel-Lindau Tumor Suppressor, E3 Ubiquitin Protein Ligase (VHL))
    Bindungsspezifität
    • 16
    • 15
    • 9
    • 5
    • 5
    • 3
    • 3
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    AA 6-175
    Reaktivität
    • 62
    • 38
    • 35
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    Ratte
    Wirt
    • 65
    • 13
    • 2
    Kaninchen
    Klonalität
    • 70
    • 10
    Polyklonal
    Konjugat
    • 42
    • 5
    • 3
    • 3
    • 3
    • 3
    • 3
    • 3
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 1
    Dieser VHL Antikörper ist unkonjugiert
    Applikation
    • 47
    • 27
    • 26
    • 26
    • 19
    • 17
    • 12
    • 9
    • 6
    • 4
    • 3
    • 2
    • 2
    • 1
    • 1
    Western Blotting (WB), Immunohistochemistry (IHC), Immunoprecipitation (IP), Immunocytochemistry (ICC)
    Verwendungszweck
    Polyclonal Antibody to Von Hippel Lindau Tumor Suppressor (vHL)
    Spezifität
    The antibody is a rabbit polyclonal antibody raised against vHL. It has been selected for its ability to recognize vHL in immunohistochemical staining and western blotting.
    Kreuzreaktivität
    Maus
    Aufreinigung
    Antigen-specific affinity chromatography followed by Protein A affinity chromatography
    Immunogen
    Recombinant Von Hippel Lindau Tumor Suppressor (vHL) corresdonding to Ala6~Gln175
    Isotyp
    IgG
    Top Product
    Discover our top product VHL Primärantikörper
  • Applikationshinweise

    Western blotting: 0.5-2 μg/mL

    1:500-2000 Immunohistochemistry: 5-20 μg/mL

    1:50-200 Immunocytochemistry: 5-20 μg/mL

    1:50-200 Optimal working dilutions must be determined by end user.

    Kommentare

    The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.

    Beschränkungen
    Nur für Forschungszwecke einsetzbar
  • Format
    Liquid
    Konzentration
    Lot specific
    Buffer
    PBS, pH 7.4, containing 0.02 % Sodium azide, 50 % glycerol.
    Konservierungsmittel
    Sodium azide
    Vorsichtsmaßnahmen
    WARNING: Reagents contain sodium azide. Sodium azide is very toxic if ingested or inhaled. Avoid contact with skin, eyes, or clothing. Wear eye or face protection when handling. If skin or eye contact occurs, wash with copious amounts of water. If ingested or inhaled, contact a physician immediately. Sodium azide yields toxic hydrazoic acid under acidic conditions. Dilute azide-containing compounds in running water before discarding to avoid accumulation of potentially explosive deposits in lead or copper plumbing.
    Handhabung
    Avoid repeated freeze-thaw cycles.
    Lagerung
    4 °C,-20 °C
    Informationen zur Lagerung
    Store at 4°C for frequent use. Stored at -20°C in a manual defrost freezer for two year without detectable loss of activity. Avoid repeated freeze-thaw cycles.
    Haltbarkeit
    24 months
  • Target
    VHL (Von Hippel-Lindau Tumor Suppressor, E3 Ubiquitin Protein Ligase (VHL))
    Andere Bezeichnung
    Von Hippel Lindau Tumor Suppressor (VHL Produkte)
    Synonyme
    HRCA1 antikoerper, RCA1 antikoerper, VHL1 antikoerper, pVHL antikoerper, BcDNA:RH61560 antikoerper, CG13221 antikoerper, DVhl antikoerper, Dmel\\CG13221 antikoerper, Dvhl antikoerper, VHL antikoerper, d-VHL antikoerper, d-vhl antikoerper, dVHL antikoerper, dmVHL antikoerper, vhl antikoerper, rca1 antikoerper, vhl1 antikoerper, hrca1 antikoerper, zgc:158722 antikoerper, Vhlh antikoerper, von Hippel-Lindau tumor suppressor antikoerper, von Hippel-Lindau antikoerper, von Hippel-Lindau tumor suppressor, E3 ubiquitin protein ligase antikoerper, von Hippel-Lindau disease tumor suppressor antikoerper, VHL antikoerper, Vhl antikoerper, vhl antikoerper, CpipJ_CPIJ009992 antikoerper
    Hintergrund
    HRCA1, RCA1, VHL1, Von Hippel-Lindau Syndrome
    Pathways
    Tube Formation, Signaling Events mediated by VEGFR1 and VEGFR2, Ubiquitin Proteasome Pathway
Sie sind hier:
Kundenservice